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Objectives. We tested the prognostic value of a new electrocar-
diographic (ECG) method (Perugia score) for diagnosis of left
ventricular hypertrophy (LVH) in essential hypertension and
compared it with five standard methods (Cornell voltage, Fra-
mingham criterion, Romhilt-Estes point score, left ventricular
strain, Sokolow-Lyon voltage).
Background. Several standard ECG methods for assessment of
LVH are used in the clinical setting, but a comparative prognostic
assessment is lacking.
Methods. A total of 1,717 white hypertensive subjects (mean age
52 years; 51% men) were prospectively followed up for up to 10
years (mean 3.3).
Results. At entry, the prevalence of LVH was 17.8% (Perugia
score), 9.1% (Cornell), 3.9% (Framingham), 5.2% (Romhilt-
Estes), 6.4% (strain) and 13.1% (Sokolow-Lyon). During follow-up
there were 159 major cardiovascular morbid events (33 fatal). The
event rate was higher in the subjects with than in those without
LVH (all p < 0.001) according to all methods except the Sokolow-
Lyon method. By multivariate analysis, an independent associa-
tion between LVH and cardiovascular disease risk was maintained
by the Perugia score (hazard ratio [HR] 2.04, 95% confidence
interval [CI] 1.5 to 2.8) and the Framingham (HR 1.91, 95% CI
1.1 to 3.2), Romhilt-Estes (HR 2.63, 95% CI 1.7 to 4.1) and strain
methods (HR 2.11, 95% CI 1.4 to 3.2). The Perugia score showed
the highest population-attributable risk for cardiovascular events,
accounting for 15.6% of all cases, whereas the Framingham,
Romhilt-Estes and strain methods accounted for 3.0%, 7.4% and
6.8% of all events, respectively. LVH diagnosed by the Perugia
score was also associated with an increased risk of cardiovascular
mortality (HR 4.21, 95% CI 2.1 to 8.7), with a population-
attributable risk of 37.0%.
Conclusions. The Perugia score carried the highest population-
attributable risk for cardiovascular morbidity and mortality com-
pared with classic methods for detection of LVH. Traditional
interpretation of standard electrocardiography maintains an im-
portant role for cardiovascular risk stratification in essential
hypertension.
(J Am Coll Cardiol 1998;31:383–90)
©1998 by the American College of Cardiology
Because of its established clinical value, broad availability and
low cost (1–3), standard electrocardiography is recommended
as the routine test for detection of left ventricular hypertrophy
(LVH) in patients with essential hypertension (4). LVH de-
tected with standard electrocardiography is a strong and
independent predictor of future cardiovascular complications,
including angina pectoris, myocardial infarction, stroke, con-
gestive heart failure and sudden cardiac death (5–9).
Several electrocardiographic (ECG) methods for detection
of LVH are used in the clinical setting. Differences have been
reported among these criteria in terms of diagnostic perfor-
mance (10,11). Although it is reasonable to speculate that
criteria with different diagnostic accuracy might differ in terms
of prediction of cardiovascular risk, a comparative assessment
of the prognostic significance of different ECG criteria of LVH
is still lacking.
Consequently, we examined data from the Progetto Iper-
tensione Umbria Monitoraggio Ambulatoriale (PIUMA) study
to compare the prognostic value of five established ECG
diagnostic criteria of LVH (2,3,12–14) with that of a cumulative
score recently developed in our laboratory (11). The new method,
which requires positivity of at least one of the following three
criteria: sum of the amplitudes of the S wave on lead V3 and the
R wave on lead aVL (SV3 1 RaVL) .2.4 mV (men) or .2.0 mV
(women), left ventricular strain or a Romhilt-Estes score of
five or more points, yielded values of sensitivity, specificity and
accuracy of 34%, 93% and 73%, respectively, in subjects with
uncomplicated essential hypertension (11).
Methods
PIUMA study. The PIUMA study is a prospective registry
of cardiovascular morbidity and mortality in adult white sub-
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jects with essential hypertension that was started in June 1986
in three participating hospitals (Perugia, Citta` della Pieve,
Castiglione del Lago) in Umbria, Central Italy. The study design
and selection criteria have been reported previously (15–17).
Patients. All patients were referred to our centers for
baseline evaluation by a group of general practitioners. The
initial evaluation included a detailed clinical examination, 12-lead
ECG, 24-h off-therapy ambulatory BP monitoring, screening
laboratory tests, funduscopic examination and, from October
1987, an M-mode and Doppler echocardiographic study ac-
cording to a standardized protocol (15). The present analysis
involves 1,784 subjects consecutively enrolled in the PIUMA
registry up to June 1995, including those investigated in a
previous study that tested the accuracy of several ECG criteria
for LVH, with echocardiographic LV mass as reference (11).
All patients had clinical systolic BP $140 mm Hg or
diastolic BP $90 mm Hg, or both, on at least three visits at
1-week intervals and fulfilled the following inclusion criteria:
no previous antihypertensive treatment (68%) or treatment
withdrawn for at least 4 weeks; no clinical or laboratory
evidence of heart failure, valvular defects, secondary causes of
hypertension or other concomitant important disease; at least
one valid BP measurement/hour over 24 h. Forty-eight subjects
(2.7%) were excluded from the present study because of ECG
exclusion criteria (see Standard electrocardiography).
Clinical BP was measured by a physician with a mercury
sphygmomanometer in the outpatient clinic in a quiet and
relaxed environment, with the subject seated for at least
10 min. The average of three measurements was used for the
analysis. Ambulatory BP was recorded using an oscillometric
device (SpaceLabs 5200, 90202 and 90207, SpaceLabs) set to
take a reading every 15 min for 24 h. Daytime and nighttime
periods were defined as the periods of wakefulness and sleep
on the basis of patient diaries. Reading, editing and analysis of
data were done as previously described (15). Subjects were
determined to have white-coat hypertension if their daytime
systolic/diastolic BP was ,130/80 mm Hg; otherwise, they were
diagnosed as having sustained hypertension (18,19).
Standard electrocardiography. Standard 12-lead ECGs
were recorded in all subjects at 25 mm/s and 1-mV/cm
calibration. Tracings were coded and interpreted by two inves-
tigators (G.S., P.V.) without knowledge of other patient data.
Interobserver differences, which occurred ,5% of readings,
were resolved by consensus. Subjects with complete bundle
branch block, previous myocardial infarction, Wolff-
Parkinson-White syndrome and atrial fibrillation were ex-
cluded from the present study. No subject was being treated
with digitalis. We tested the following ECG criteria for LVH:
Sokolow-Lyon voltage (sum of the amplitudes of the S wave on
lead V1 and the R wave on lead V5 or V6 $3.5 mV) (2);
Romhilt-Estes point score (both partition values of $5 points
and $4 points were examined) (3); gender-specific Cornell
voltage (SV3 1 RaVL .2.8 mV in men and .2.0 mV in women)
(12); Framingham criterion (coexistence of a definite strain
pattern and at least one of the following voltage criteria: sum
of the amplitudes of the R wave on lead I and the S wave on
lead III $2.5 mV, sum of the amplitudes of the S wave on lead
V1 or V2 and the R wave on lead V5 or V6 $3.5 mV, the S
wave on the right precordial lead $2.5 mV and the R wave on
the left precordial lead $2.5 mV) (13); left ventricular strain
($0.1-mV ST segment depression with asymmetric T wave
inversion on leads V2 to V6 and either lateral or inferior
peripheral leads; minor ST-T wave abnormalities were coded
as negative) (14). We also tested a simple cumulative score
recently developed in our laboratory (Perugia score) that
requires positivity of one or more of the following three
criteria: SV3 1 RaVL .2.4 mV (men) or .2.0 mV (women),
left ventricular strain or a Romhilt-Estes score of five or more
points (11). When compared with traditional criteria for ECG
diagnosis of LVH, the Perugia score showed the highest
sensitivity (34%) at the expense of a slight decrease in speci-
ficity (93%), whereas, for example, the Cornell voltage (12)
yielded a sensitivity of 16% and a specificity of 97% (11).
Follow-up procedures. All subjects were followed up by
their family doctors in cooperation with the outpatient clinic of
the referring hospital and were treated with the aim of
reducing clinical BP to ,140/90 mm Hg using standard lifestyle
and pharmacologic measures. Diuretic drugs, beta adrenergic
blocking agents, angiotensin-converting enzyme inhibitors, cal-
cium channel blockers and alpha-blockers, alone or in various
combinations, were the antihypertensive drugs most frequently
used. There were periodic contacts with family doctors and
telephone interviews with patients to ascertain vital status and
the occurrence of major cardiovascular complications. All
interviews were conducted without knowledge of the patient’s
clinical data. Many of the patients continued to be periodically
referred to our institutions for BP control and other diagnostic
procedures. A major effort was recently undertaken over ;1
month to assess the vital status of all subjects. Nineteen
subjects (1.1%) could not be contacted for follow-up or
refused to provide information. These 19 subjects did not differ
significantly in age and clinical characteristics from the 1,717
patients for whom complete follow-up data were obtained.
End point evaluation. Available hospital record forms and
other source documents of patients who died or had a cardio-
vascular event were reviewed in conference by us, without
knowledge of the results of ambulatory BP monitoring, ECG,
echocardiography or the other procedures carried out at entry
into the PIUMA study. Cardiovascular events included new-
onset coronary artery disease (myocardial infarction or angina
with concomitant ischemic ECG changes), stroke, transient
Abbreviations and Acronyms
BP 5 blood pressure
CI 5 confidence interval
ECG 5 electrocardiogram, electrocardiographic
HR 5 hazard ratio
LVH 5 left ventricular hypertrophy
PIUMA 5 Progetto Ipertensione Umbria Monitoraggio
Ambulatoriale (trial)
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cerebral ischemia, symptomatic aortoiliac occlusive disease
verified at angiography, thrombotic occlusion of a retinal
artery documented at angiography, congestive heart failure
requiring hospitalization or renal failure requiring dialysis. The
international standard criteria used to diagnose cardiovascular
events in the PIUMA study have been described elsewhere
(15–17).
Data analysis. Results are reported as mean value 6 SD.
Standard descriptive and comparative statistical analyses were
undertaken. We compared the two hypertensive groups (with
and without LVH according to the various criteria) in terms of
cardiovascular morbidity, expressed as the combined number
of fatal plus nonfatal cardiovascular events over the follow-up
period. Event rates are presented as the number of events/100
patient-years based on the ratio of the observed number of
events to the total number of patient-years of exposure. For
the subjects who experienced multiple nonfatal events, the
analysis included only the first event. Survival curves were
estimated using the Kaplan-Meier product-limit method (20)
and compared by the Mantel (log-rank) test (21). The effect of
prognostic factors on survival was evaluated by stepwise Cox
semiparametric regression models (22). We tested the follow-
ing covariates in the Cox models: age (#40 years, 41 to 60
years, $60 years); gender (women, men); diabetes (no, yes);
clinical BP (grouped by Joint National Committee V class [4]);
ambulatory BP (white-coat hypertension, sustained hyperten-
sion); serum cholesterol (mmol/liter), smoking habits (current
smokers, previous smokers, never-smokers); body mass index
(kg/m2); LVH at ECG (no, yes; each criterion was entered into
the model separately); antihypertensive therapy at follow-up
contact (lifestyle measures, drug treatment). Age was analyzed
as a categoric variable because of an abrupt increase in risk
after age 60, with consequent failure to pass the linearity test.
Population-attributable risk is an estimate of the proportion of
cardiovascular morbid events that can be attributed to a given
risk marker, taking into account its prevalence and hazard
ratio, and was defined as
Prevalencez~Hazard ratio 2 1!
Prevalencez~Hazard ratio 2 1! 1 1
z100,
where prevalence is the number of patient-years of observation
with a risk factor present divided by the total observation time
(23). In two-tailed tests, p values ,0.05 were considered
statistically significant. BMDP Statistical Software, version 7,
was used to perform the analysis.
Results
Clinical characteristics. As shown in Table 1, the preva-
lence of ECG LVH differed among the tested criteria, ranging
from 3.9% (Framingham method) to 17.8% (Perugia score).
The clinical characteristics of the study cohort are reported in
Table 2. Patients with LVH detected by the Perugia score were
older, had a longer duration of hypertension and a more
frequent history of previous use of antihypertensive drugs
compared with subjects without LVH. Clinical and 24-h sys-
tolic and diastolic BP values were higher in the subset with
LVH (all p , 0.001).
During follow-up, 67% of patients with LVH were treated
with antihypertensive drugs compared with 49% of patients
without LVH (p , 0.001). The distribution of beta-blockers
and diuretic drugs, alone or combined; calcium-channel block-
ers and angiotensin-converting enzyme inhibitors, alone or
combined; and that of different drug combinations did not
differ between the two groups (LVH: 14%, 22% and 31%; no
LVH: 10%, 20%, and 19%, respectively).
When LVH was defined according to the other tested
criteria, patients with LVH were significantly older (with the
exception of Sokolow-Lyon voltage, 51 versus 52 years, p 5
NS) and had a longer duration of hypertension and higher
clinical and 24-h BP values than patients without LVH (all p ,
0.01).
Cardiovascular morbidity. Complete follow-up data were
obtained for all 1,717 subjects, who contributed 5,606 patient-
Table 1. Prevalence of Left Ventricular Hypertrophy
at Electrocardiography
Method (ref no.) No. (%)
Cornell voltage (12) 157 (9.1)
Framingham criterion (13) 67 (3.9)
Romhilt-Estes score ($5 points) (3) 90 (5.2)
Romhilt-Estes score ($4 points) (3) 107 (6.2)
Left ventricular strain (14) 111 (6.5)
Sokolow-Lyon voltage (2) 225 (13.1)
Perugia score (11) 306 (17.8)
ref 5 reference.
Table 2. Clinical Characteristics of Subjects With and Without Left
Ventricular Hypertrophy at Electrocardiography According to the
New Method (Perugia score)
All Patients
(n 5 1,717)
No LVH
(n 5 1,411)
LVH
(n 5 306)
p
Value
Age (yr) 52 (12) 51 (12) 56 (12) , 0.0001
Men 51% 51% 53% 0.54
BMI (kg/m2) 26.8 (4) 26.8 (4) 27.1 (4) 0.19
Current smoker 23% 22% 24% 0.63
Diabetes 8% 7% 9% 0.25
Prev CV events 2% 2% 3% 0.18
Alcohol intake (g/day) 20 (32) 19 (30) 25 (40) , 0.005
Duration of HTN (yr) 4.5 (6) 4.3 (6) 5.5 (7) , 0.002
Prev anti-HTN therapy 32% 30% 42% , 0.0001
Clinical SBP (mm Hg) 157 (19) 155 (18) 166 (21) , 0.0001
Clinical DBP (mm Hg) 97 (10) 97 (9) 99 (12) 0.001
24-h SBP (mm Hg) 138 (15) 136 (14) 147 (17) , 0.0001
24-h DBP (mm Hg) 87 (10) 86 (10) 90 (12) 0.0001
Serum chol (mmol/liter) 5.55 (1.1) 5.54 (1.1) 5.58 (1.1) 0.54
HDL chol (mmol/liter) 1.25 (0.4) 1.25 (0.3) 1.26 (0.5) 0.76
Serum TGs (mmol/liter) 1.70 (1.2) 1.67 (1.2) 1.78 (1.2) 0.19
Data presented are mean value (SD) or percent of patients. BMI 5 body
mass index; chol 5 cholesterol; CV 5 cardiovascular; DBP 5 diastolic blood
pressure; HDL 5 high density lipoprotein; HTN 5 hypertension; LVH 5 left
ventricular hypertrophy; Prev 5 previous; SBP 5 systolic blood pressure; TGs 5
triglycerides.
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years of observation. During up to 10.2 years of follow-up
(mean [6SD] 3.27 6 2.2 years), there were 159 new cardio-
vascular morbid events (33 fatal, 126 nonfatal), and the event
rate was 2.84/100 patient-years in the overall study group.
There were 51 subjects with stroke (11 fatal), 28 with myocar-
dial infarction (4 fatal), 13 with sudden cardiac death, 5 with
cardiac death from other causes, 13 with transient cerebral
ischemia, 23 with new-onset coronary artery disease, 8 with
heart failure requiring hospital admission, 12 with new-onset
aortoiliac occlusive disease, 2 with occlusion of the retinal
artery and 4 with renal failure requiring dialysis.
When LVH was defined according to the Perugia score, the
event rate was 5.83/100 patient-years in the group with and
2.19/100 patient-years in the group without LVH. Event-free
survival curves differed between the two groups (p , 0.001,
log-rank test) (Fig 1). The unadjusted event rate was higher in
subjects with than in those without LVH (all p , 0.001)
according to all ECG criteria except the Sokolow-Lyon method
(Table 3). However, ECG LVH detected by the Cornell
voltage lost its prognostic significance in a multivariate Cox
model after adjustment for the other significant covariates
(adjusted hazard ratio [HR] 1.34, 95% confidence interval [CI]
0.86 to 2.08). An excess risk for cardiovascular disease was
associated with ECG LVH only by the Perugia score (HR 2.04,
95% CI 1.47 to 2.80); the Framingham criterion (HR 1.91,
95% CI 1.13 to 3.23); left ventricular strain (HR 2.11, 95% CI
1.40 to 3.20); and the Romhilt-Estes score, both with a cutoff of
five or more points (HR ratio 2.63, 95% CI 1.69 to 4.10) and
four or more points (HR 2.43, 95% CI 1.59 to 3.71). When
these five ECG criteria for LVH were entered together into
the Cox model, only the Perugia score (HR 1.66, 95% CI 1.12
to 2.47, p 5 0.015) and the Romhilt-Estes score (HR 1.82, 95%
CI 1.08 to 3.060, p 5 0.03) yielded significance. Because of its
higher prevalence, ECG LVH detected by the Perugia score
carried the highest population-attributable risk for cardiovas-
cular events, accounting for 15.6% of all cases. By comparison,
ECG LVH detected by the Framingham and Romhilt-Estes
criteria accounted for only 3.0% and 7.4% of all events,
respectively. Table 4 reports the other significant independent
predictors of total cardiovascular morbid events. Age, previous
cardiovascular morbid events, diabetes, cigarette smoking and
clinical and ambulatory BP were additional independent pre-
Figure 1. Event-free survival curves for total cardiovascu-
lar events (left) in the study cohort grouped by the presence
or absence of LVH according to the Perugia score (11).
The rate of major cardiovascular morbid events (right) was
significantly higher in the subset with LVH.
Table 3. Total Cardiovascular Morbid Events as a Function of Baseline Electrocardiography
Criterion
Prevalence
(%)
CV Morbidity
(3100 pt-yr)
Unadjusted
HR
Adjusted HR
(95% CI)
Population-
Attributable
Risk (%)No LVH LVH
Cornell voltage 9.1 2.65 4.68 1.77 1.34 (0.86–2.08) 3.0
Framingham criterion 3.9 2.66 7.26 2.73 1.91 (1.13–3.23)* 3.5
Romhilt-Estes $5 points 4.9 2.53 8.75 3.46 2.63 (1.69–4.10)* 7.4
Romhilt-Estes $4 points 5.9 2.52 7.90 3.13 2.43 (1.59–3.71)* 7.7
Left ventricular strain 6.5 2.53 7.64 3.02 2.11 (1.40–3.20)* 6.8
Sokolow-Lyon voltage 14.3 2.79 3.13 1.12 1.19 (0.77–1.83) 2.6
Perugia score 17.8 2.19 5.83 2.66 2.04 (1.47–2.80)* 15.6
*p , 0.01. CI 5 confidence interval; HR 5 hazard ratio adjusted for age, diabetes, smoking, previous cardiovascular
(CV) events, clinical blood pressure (Joint National Committee, fifth report, class [4]) and ambulatory blood pressure
(white-coat versus ambulatory hypertension); LVH 5 left ventricular hypertrophy; Prevalence 5 patient-years (pt-yr) of
observation with that criterion divided by the total patient-years of observation.
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dictors of cardiovascular morbidity. Gender, serum choles-
terol, body mass index and antihypertensive therapy at the
follow-up contact were tested but not entered into the model.
Cardiovascular mortality. Cardiovascular mortality was
higher in subjects with than in those without LVH (all p ,
0.001) according to all ECG criteria except the Sokolow-Lyon
criteria (Table 5). Figure 2 shows survival curves of subgroups
with and without ECG LVH detected by the Perugia score
(log-rank test, p , 0.001). Age, previous cardiovascular morbid
events, diabetes and ECG LVH (detected with the Perugia
method, the Romhilt-Estes method or left ventricular strain)
were the only independent predictors of cardiovascular mor-
tality in a Cox model (Table 6). When these three ECG criteria
for LVH were entered together into the Cox model, only the
Perugia score (HR 4.07, 95% CI 2.01 to 8.26, p 5 0.0001)
yielded significance. ECG LVH detected by the Perugia score
carried the highest population-attributable risk for cardiovas-
cular mortality, accounting for 37.0% of all fatal events (Table
5).
Discussion
To our knowledge, the present study is the first comparative
prognostic assessment of several traditional ECG methods for
diagnosis of LVH in patients with essential hypertension. After
adjustment for concomitant risk factors in a multivariate
model, cardiovascular disease risk independently attributable
to ECG LVH was considerably higher with the new method
(Perugia score) than with other standard methods.
ECG LVH and cardiovascular risk. More than 25 years
ago, the Framingham Heart Study (6,7) showed that the risk of
fatal and nonfatal cardiovascular morbid events was from
threefold to eightfold higher in middle-aged persons with ECG
LVH than in normal adults of similar age, and this finding
remained significant after adjustment for coexistent risk fac-
tors. The adverse prognostic impact of ECG LVH has been
confirmed in other investigations (8,9). The present study
provides further evidence that ECG LVH is an independent
risk factor for cardiovascular morbidity and mortality in pa-
tients with essential hypertension and extends previous find-
ings by evaluating the prognostic contribution of different ECG
criteria for LVH. We used multivariate proportional hazards
modeling to determine the relative and attributable risks of
LVH for cardiovascular morbidity.
One major limitation of electrocardiography is its low
sensitivity for detection of LVH. Hence, many subjects with a
significant increase in left ventricular mass may remain undi-
agnosed by electrocardiography. For example, the prevalence
of ECG LVH detected by the Framingham method in the
general population (voltage criteria plus concomitant “strain
pattern”) was only 2% (13). Although the sensitivity of several
ECG criteria for LVH may be acceptable, albeit low (from
58% for the Romhilt-Estes score [3] to 41% for the Cornell
voltage [12]), among patients with disparate cardiac disorders,
the sensitivity of electrocardiography for detection of LVH
consistently decreases in the general population or in un-
selected hypertensive patient groups. For example, the sensi-
tivity of the gender-specific Cornell voltage criterion was only
10% in men and 22% in women in the Framingham Heart
Study (13) and 12% in men and 19% in women in the PIUMA
Table 5. Fatal Cardiovascular Morbid Events as a Function of Baseline Electrocardiography
Criterion
Prevalence
(%)
CV Mortality
(3100 pt-yr)
Unadjusted
HR
Adjusted HR
(95% CI)
Population-
Attributable
Risk (%)No LVH LVH
Cornell voltage 9.1 0.48 1.53 3.19 2.02 (0.87–4.69) 16.9
Framingham criterion 3.9 0.49 2.13 4.34 2.45 (0.92–6.53) 5.7
Romhilt-Estes $5 points 4.9 0.44 2.76 6.27 4.46 (1.91–10.38)* 15.2
Romhilt-Estes $4 points 5.9 0.43 2.60 6.04 4.89 (2.16–11.13)* 19.3
Left ventricular strain 6.5 0.40 3.00 7.50 4.58 (2.18–9.61)* 19.3
Sokolow-Lyon voltage 14.3 0.53 0.74 1.40 1.81 (0.71–4.58) 10.5
Perugia score 17.8 0.30 1.75 5.83 4.21 (2.05–8.66)* 37.0
*p , 0.001. HR 5 hazard ratio adjusted for age, diabetes and previous cardiovascular (CV) events; other
abbreviations as in Table 3.
Table 4. Independent Predictors of Total Cardiovascular Morbid
Events (Cox model)*
Adjusted HR
(95% CI)
p
Value
Age
.60 versus , 40 yr 7.24 (2.88–18.19) , 0.0001
40–60 versus , 40 yr 3.27 (1.32–8.10) , 0.003
Prev CV events 2.45 (1.32–4.56) , 0.02
Diabetes 2.54 (1.76–3.66) , 0.0001
Cigarette smoking 2.01 (1.24–3.26) , 0.009
Ambulatory BP, sustained
versus white-coat HTN
3.70 (1.15–11.62) , 0.007
Clinical BP (by JNC V class)
Class 2 versus class 1 1.40 (0.95–2.07) NS
Class 3 versus class 1 1.43 (0.90–2.27) NS
Class 4 versus class 1 2.80 (1.46–5.37) , 0.0001
*The independent contribution of left ventricular hypertrophy on electro-
cardiography is reported in Table 3. BP 5 blood pressure; JNC V 5 fifth report
of the Joint National Committee (4); other abbreviations as in Table 2.
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study (11). One possible reason for these discrepancies may be
that the sensitivity of electrocardiography increases with sever-
ity of LVH (11,13), whereas, conversely, severe LVH is
uncommon in the general population or in unselected hyper-
tensive patient groups.
Different ECG criteria for LVH. Cardiac electric events
recorded at the skin surface may be attenuated by several
extracardiac factors (body size, adipose tissue, lung tissue,
pericardial fluid and epicardial fat). Consequently, the choice
of progressively lower voltage partition values to increase
sensitivity is invariably outweighed by a decrease in specificity.
Several factors, such as age (13), gender (13,24), obesity
(13,25,26) and cigarette smoking (13,27), have an adverse
impact on the ECG sensitivity for LVH. Nevertheless, fixed
voltage criteria continue to be widely used in clinical practice
as inexpensive and easily available screening tools for LVH,
although more sophisticated computer-assisted analyses can
improve the accuracy of electrocardiography (28,29). As a
consequence of these shortcomings, the relation between ECG
voltages and left ventricular mass is weak (12,30,31). Among
the various QRS voltages, the Cornell voltage (SV3 1 RaVL)
showed the closest association with left ventricular mass
(11,30,31), and its performance was superior to that of the
Sokolow-Lyon voltage in a receiver operator characteristic
curve analysis (11). The Perugia score incorporates a gender-
specific Cornell voltage with a modified partition value (.2.4 mV
in men, .2.0 mV in women) that was generated through the
use of receiver operator characteristic curve analysis, together
with a left ventricular strain pattern and a Romhilt-Estes score
of five or more (11). Left ventricular strain has also been
reported (11) as a reliable sign of LVH in the absence of
increased QRS voltage (2,14) and showed a specificity of 98%
for LVH in hypertensive subjects without overt coronary heart
disease and not taking digoxin (11). The Romhilt-Estes score,
which combines QRS voltage and voltage-independent signs
(QRS duration, retardation of the deflection of the highest
point of the ECG wave, left atrial enlargement, left-axis
deviation and left ventricular strain), showed a specificity of
100% for LVH (11).
In the present investigation, LVH detected at electrocardi-
ography by the Perugia score showed the highest attributable
risk for cardiovascular disease compared with other standard
criteria. These differences may be explained by the finding that
LVH detected using the Perugia score showed the highest
prevalence (17.8%) among the tested ECG criteria, in associ-
ation with an age- and risk factor-adjusted relative risk for
cardiovascular disease that was only marginally lower than
both the Romhilt-Estes partitions and the Framingham and
strain methods. Thus, compared with the other classic criteria,
the Perugia score allowed diagnosis of LVH in a larger group
of patients whose high risk of subsequent events was compa-
rable to that of the minority of patients diagnosed using the
more specific but less sensitive traditional methods. Because
the Romhilt-Estes score and the Perugia score incorporate a
left ventricular strain pattern in their definition, an underlying
condition of myocardial ischemia, possibly reflected by a
typical strain pattern, might contribute to explain their prog-
nostic value beyond that directly attributable to increased left
ventricular mass.
The mechanisms that link LVH to cardiovascular morbidity
and mortality are unclear. In essential hypertension, left
ventricular mass may be considered a marker that reflects and
Figure 2. Event-free survival curves for fatal cardiovascu-
lar events (left) in the study cohort grouped by the
presence or absence of LVH according to the Perugia
score (11). The rate of fatal cardiovascular morbid events
(right) was significantly higher in the subset with LVH.
Table 6. Independent Predictors of Fatal Cardiovascular Events
(Cox model)*
Adjusted HR
(95% CI)
Age . 60 vs. , 40 yr 10.1 (3.71–27.44)†
Previous CV event 3.96 (1.31–11.97)†
Diabetes 3.97 (1.94–8.58)†
*The independent contribution of left ventricular hypertrophy on electro-
cardiography is reported in Table 5. †p , 0.01. Abbreviations as in Table 3.
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integrates the long-term detrimental effects of high BP and
other cardiovascular risk factors. Increased left ventricular
mass is associated with an increased risk for ventricular
arrhythmias (32–34) and sudden cardiac death (35–37).
Strengths and limitations of the study. The PIUMA study
provides an opportunity for elucidating the prognostic value of
several risk markers in subjects with uncomplicated essential
hypertension. In the present analysis, ambulatory BP was
included among the tested covariates because there is evidence
of its independent prognostic value (15,19,38–40), and clinical
BP was scored by Joint National Committee V (4) stage to
incorporate both systolic and diastolic BP values for risk
prediction. The possible influence of significant valvular de-
fects on LVH was excluded by clinical examination and
Doppler echocardiography.
A limitation of this study was that no more than 40% of
subjects had regular clinical visits at follow-up, and thus we
were unable to adjust for potentially relevant factors, including
degree of BP control and changes in LVH over time. More-
over, our findings were obtained in a 100% white cohort and
cannot be extended to other racial groups. Finally, we did not
assess the prognostic impact of more sophisticated analyses of
electrocardiography, such as the computer-assisted computa-
tion of the QRS time-voltage integral (29,30) and the comput-
erized or manual calculation of the 12-lead voltage-duration
product (31), which have been shown to improve the accuracy
of electrocardiography for identification of LVH (29–31,41).
Clinical implications. Electrocardiography is currently rec-
ommended as the first-line method for detection of LVH in
patients with hypertension (4). The present study confirms that
ECG diagnosis of LVH in these patients predicts a twofold to
fourfold increase in age- and risk factor-adjusted cardiovascu-
lar morbidity and mortality. Compared with traditional ECG
methods, the Perugia score allowed detection of LVH in a
large proportion of subjects (17.8%) and carried the highest
attributable risk for cardiovascular morbidity and mortality.
Taken together, these data suggest that traditional interpreta-
tion of the standard ECG maintains an important role for
cardiovascular risk stratification in essential hypertension. The
promising role of more sophisticated computer-assisted tech-
niques for ECG analysis (29–31,41) will require widescale
testing and prognostic validation.
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